UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4693-4700

2009

Volltextzugriff (PDF)

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

Breast cancer research : BCR, 2010-01, Vol.12 (1), p.R12-R12, Article R12

2010

Volltextzugriff (PDF)

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015

Seminars in radiation oncology, 2016, Vol.26 (1), p.59-70

2016

Volltextzugriff (PDF)

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1539-1548

2020

Volltextzugriff (PDF)

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Breast cancer research : BCR, 2010-11, Vol.12 (6), p.R95-R95, Article R95

2010

Volltextzugriff (PDF)

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

Clinical cancer research, 2015-05, Vol.21 (10), p.2305-2314

2015

Volltextzugriff (PDF)

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

Nature genetics, 1999-10, Vol.23 (2), p.166-175

1999

Volltextzugriff (PDF)

Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program

Gynecologic oncology, 2006, Vol.100 (1), p.149-151

2006

Volltextzugriff (PDF)

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Cancer cell, 2003-05, Vol.3 (5), p.459-469

2003

Volltextzugriff (PDF)

Genetics: Predisposition and Management

Clinical obstetrics and gynecology, 2011-03, Vol.54 (1), p.180-190

LEGARE, ROBERT D

2011

Volltextzugriff (PDF)

Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program

Gynecologic oncology, 2010-03, Vol.116 (3), p.295-300

2010

Volltextzugriff (PDF)

Is Tumor Board Relevant?

The breast journal, 2013-05, Vol.19 (3), p.351-353

2013

Volltextzugriff (PDF)

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

The New England journal of medicine, 2003-03, Vol.348 (13), p.1201-1214

2003

Volltextzugriff (PDF)

Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.GS6-03-GS6-03

2020

Volltextzugriff (PDF)

Abstract P2-16-19: Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H+BC): A Brown University oncology group (BrUOG) study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-16-19

2020

Volltextzugriff (PDF)

Risk factors for breast cancer

Obstetrics and gynecology clinics of North America, 2002-03, Vol.29 (1), p.159-172

2002

Volltextzugriff (PDF)

Adjuvant therapy in breast cancer

Obstetrics and gynecology clinics of North America, 2002-03, Vol.29 (1), p.201-208

2002

Volltextzugriff (PDF)

The identification and management of hereditary breast and ovarian cancer

Medicine and health, Rhode Island, 2003-02, Vol.86 (2), p.48

2003

Volltextzugriff (PDF)

Myelodysplastic syndrome

Current opinion in hematology, 1995, Vol.2 (4), p.283-292

1995

Volltextzugriff (PDF)

Linkage of a Familial Platelet Disorder With a Propensity to Develop Myeloid Malignancies to Human Chromosome 21q22.1-22.2

Blood, 1996-06, Vol.87 (12), p.5218-5224

1996

Volltextzugriff (PDF)

Adjuvant therapy in breast cancer: Breast Disease: Diagnosis and Contemporary Management

Obstetrics and gynecology clinics of North America, 2002, Vol.29 (1)

2002

Volltextzugriff (PDF)

Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study

Blood, 1998-06, Vol.91 (12), p.4496-4503

1998

Volltextzugriff (PDF)

Risk factors for breast cancer: Breast Disease: Diagnosis and Contemporary Management

Obstetrics and gynecology clinics of North America, 2002, Vol.29 (1)

2002

Volltextzugriff (PDF)

Ovarian Cancer

Surgical oncology clinics of North America, 1998-04, Vol.7 (2), p.317-333

1998

Volltextzugriff (PDF)

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target ofimatinib in idiopathic hypereosinophilic syndrome

The New England journal of medicine, 2003, Vol.348 (13), p.1201-1214

2003

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(72)
Französisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease

Genetics: Predisposition and Management

Addressing clinical trials: Can the Multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program

Is Tumor Board Relevant?

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031)

Abstract P2-16-19: Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H+BC): A Brown University oncology group (BrUOG) study

Risk factors for breast cancer

Adjuvant therapy in breast cancer

The identification and management of hereditary breast and ovarian cancer

Myelodysplastic syndrome

Linkage of a Familial Platelet Disorder With a Propensity to Develop Myeloid Malignancies to Human Chromosome 21q22.1-22.2

Adjuvant therapy in breast cancer: Breast Disease: Diagnosis and Contemporary Management

Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study

Risk factors for breast cancer: Breast Disease: Diagnosis and Contemporary Management

Ovarian Cancer

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target ofimatinib in idiopathic hypereosinophilic syndrome

Suchergebnisse filtern